34results about How to "Not improve" patented technology

Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and / or improvement of wound healing and / or tissue repair.

Conventional oligonucleotides are opened at both ends and thereby unstable. Their stability against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes toxicity. The present invention provides oligonucleotides and medicaments in which these problems are improved. That is, it provides staple oligonucleotides and medicaments containing the same as the active ingredient. Specifically, it provides transcription factor inhibitors, antisense oligonucleotides and siRNAs. More specifically, it provides agents for preventing, treating or improving inflammation, autoimmune diseases, central diseases, reperfusion injury in ischaemic diseases, worsened prognosis after organ transplantation or organ surgery, or restenosis after PTCA. Further specifically, it provides agents for preventing, treating or improving arthritis, dermatitis, nephritis, hepatitis, renal failure, cystitis, prostatitis, urethritis, ulcerative colitis, Crohn disease, chronic rheumatoid arthritis, osteoarthritis, atopic dermatitis, contact dermatitis, psoriasis, cutaneous ulcer or decubitus.

The invention provides compositions and methods for the prevention, diagnosis, or treatment of conditions affecting breast tissue. The compositions can include one or more therapeutic agents or diagnostic agents, and an effective carrier. The composition can be specifically adapted for transdermal permeation through the mammary papilla, areola, or a combination thereof, and into underlying breast tissue.

Insulated-gate field-effect transistors (“IGFETs”), both symmetric and asymmetric, suitable for a semiconductor fabrication platform that provides IGFETs for analog and digital applications, including mixed-signal applications, utilize empty-well regions in achieving high performance. A relatively small amount of semiconductor well dopant is near the top of each empty well. Each IGFET (100, 102, 112, 114, 124, or 126) has a pair of source / drain zones laterally separated by a channel zone of body material of the empty well (180, 182, 192, 194, 204, or 206). A gate electrode overlies a gate dielectric layer above the channel zone. Each source / drain zone (240, 242, 280, 282, 520, 522, 550, 552, 720, 722, 752, or 752) has a main portion (240M, 242M, 280M, 282M, 520M, 522M, 550M, 552M, 720M, 722M, 752M, or 752M) and a more lightly doped lateral extension (240E, 242E, 280E, 282E, 520E, 522E, 550E, 552E, 720E, 722E, 752E, or 752E). Alternatively or additionally, a more heavily doped pocket portion (250 or 290) of the body material extends along one of the source / drain zones. When present, the pocket portion typically causes the IGFET to be an asymmetric device.

Methods are provided for using methotrexate (MTX) in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of MTX in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2′-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.

Insulated-gate field-effect transistors (“IGFETs”), both symmetric and asymmetric, suitable for a semiconductor fabrication platform that provides IGFETs for analog and digital applications, including mixed-signal applications, utilize empty-well regions in achieving high performance. A relatively small amount of semiconductor well dopant is near the top of each empty well. Each IGFET (100, 102, 112, 114, 124, or 126) has a pair of source / drain zones laterally separated by a channel zone of body material of the empty well (180, 182, 192, 194, 204, or 206). A gate electrode overlies a gate dielectric layer above the channel zone. Each source / drain zone (240, 242, 280, 282, 520, 522, 550, 552, 720, 722, 752, or 752) has a main portion (240M, 242M, 280M, 282M, 520M, 522M, 550M, 552M, 720M, 722M, 752M, or 752M) and a more lightly doped lateral extension (240E, 242E, 280E, 282E, 520E, 522E, 550E, 552E, 720E, 722E, 752E, or 752E). Alternatively or additionally, a more heavily doped pocket portion (250 or 290) of the body material extends along one of the source / drain zones. When present, the pocket portion typically causes the IGFET to be an asymmetric device.

Systems and methods for rotating shield brachytherapy. In an aspect, some of the systems and methods can be used to facilitate shield selection for use in rotating shield brachytherapy. In an aspect, the invention is a shielded needle or catheter system with a rotational controller for delivering radioisotope-based interstitial rotating shield brachytherapy (I-RSBT). In an aspect, the catheter system can utilize paddle-based RSBT. Further provided are methods and systems for helical RSBT.

The present invention provides a color image forming apparatus forming an image by using a plurality of image carriers, wherein at least one lens having identical optical characteristics and forming individual scanning optical systems which scan the individual image carriers with beams is formed by use of a plurality of cavities. When dividing the cavities into a plurality of groups in response to variations in the optical characteristics caused by cavity difference of the lenses formed with the plurality of cavities so that the relative differences in an optical parameters are within an allowable range, at least one lens of each scanning optical system is selected from the cavities of one of the plurality of groups.

Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.

Systems and methods for rotating shield brachytherapy. In an aspect, some of the systems and methods can be used to facilitate shield selection for use in rotating shield brachytherapy. In an aspect, the invention is a shielded needle or catheter system with a rotational controller for delivering radioisotope-based interstitial rotating shield brachytherapy (I-RSBT). In an aspect, the catheter system can utilize paddle-based RSBT. Further provided are methods and systems for helical RSBT.

Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a μ-opioid receptor antagonist.

The use of a composition comprising a compound from the family of avermectins, preferably ivermectin, and doxycycline or one of the salts thereof that is pharmaceutically acceptable in the treatment and / or slowing of the appearance of the symptoms of rosacea is described.

The invention refers to a synergistic combination comprising a Sigma ligand of general formula (I), and a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament, particularly for the prophylaxis and / or treatment of pain.

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.